A New Diagnostic Method for Thyroid Carcinoma Associated with Autoantibody against Cancer Specific Antige

Not Applicable

• Conditions: Thyroid Carcinoma

• Registration Number: JPRN-UMIN000029164
• Lead Sponsor: Tottori University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-15
• Study Completion: 2021-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Not provided

Exclusion Criteria

1. Advanced thyroid carcinoma 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry 2. Inadvanced thyroid carcinoma 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry 3. Benign thyroid tumor 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry 4. Graves' disease 1) history of malignant tumor in other organs 2) post thyroidectomy 3) post I-131 ablation 4) pregnant or suspected of pregnancy 5) others not suitable for entry 5. Chronic thyroiditis 1) history of malignant tumor in other organs 2) post thyroidectomy 3) pregnant or suspected of pregnancy 4) others not suitable for entry 6. Normal control 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To investigate the titer of autoantibody against thyroid carcinoma in 6 groups (progressive thyroid carcinoma, nonprogressive thyroid carcinoma, benign thyroid nodule, Graves' disease, chronic thyroiditis, and normal control)

Secondary Outcome Measures

Name	Time	Method
1) To invastigate the change of titer in the treatment of thyroid carcinoma 2) To investigate the correlations between autoantibodies against thyroid carcinoma and clinical parameters including pathological diagnosis, cytological diagnosis, thyroid function test, thyroid autoantibodies, and imaging study 3) To investigate the safety including nonspecific antigen-antibody interaction